Figure 6

Ad5IL-12 vector treatment of TRAMP-C1 tumors can reduce percentages of CD4/Foxp3 Tregs found in the TSLN. C57BL6 mice were treated with injection of PBS, DL70-3, or the Ad5IL-12 vector while another set of mice corresponding to each of these treatment groups received an additional daily IP administration of RU486 for 1 week. At the end of this treatment, draining TSLN were isolated from individual animals and analyzed by flow cytometry for their content of CD4⁺/Foxp3⁺ T cells. A representative dot plot is shown from one set of animals out of 3 separate experiments. Cumulative data from 3 flow cytometry analyses demonstrated CD4/FoxP3 expression percentages averaged 2.27 ± 0.2 for PBS, 2.12 ± 0.3 for RU486, 1.98 ± 0.2 for DL70-3, 1.98 ± 0.2 for DL70-3 + RU486, 1.75 ± 0.4 for Ad5IL-12 and 1.64 ± 0.4 for Ad5IL-12 + RU486 treatment groups; n = 6. TSLN lymphocytes from two treated animals from each treatment were analyzed in each flow cytometry experiment.